| ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. | |
| | |
MedLine Citation:
|
PMID: 23325296 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
The anaplastic lymphoma kinase (ALK) fusion gene is a key oncogenic driver in a subset of patients with advanced non-small cell lung cancer (NSCLC). Oncogenic fusion genes, including echinoderm microtubule-associated protein-like 4 (EML4) and ALK, have been detected in approximately 2-7 % of NSCLC patients. Fluorescence in situ hybridization (FISH) is the recommended method for detecting ALK gene rearrangement. EML4-ALK fusion genes define a molecular subset of NSCLC with distinct clinical characteristic (lung adenocarcinoma, never or former smoker, usually mutually exclusive with EGFR mutations). Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive, small molecule inhibitor of both the receptor tyrosine kinases ALK and c-MET (hepatocyte growth factor receptor). Crizotinib has been shown to yield important clinical benefit such as objective response rate, progression-free survival (PFS), and anticipated improvements in quality of life when used in pretreated patients with advanced NSCLC harboring EML4-ALK gene rearrangement. Preliminary phase II data suggested that crizotinib is safe and well tolerated with rapid and robust antitumor activity. A phase III randomized trial in a second-line setting showed response rate and PFS (primary study endpoint) advantage for crizotinib as compared to second-line chemotherapy. Treatment-related adverse events, predominantly restricted to the gastrointestinal and visual systems, are generally self-limiting or easily managed. Crizotinib is a new standard of care for patients with advanced, ALK-positive, NSCLC. In this review, we will discuss the discovery of ALK rearrangements, the clinical epidemiology of lung cancer driven by ALK, the clinical data for ALK-targeted therapy in NSCLC, and ongoing ALK inhibitor-based clinical trials. |
| | |
Authors:
|
Francesca Casaluce; Assunta Sgambato; Paolo Maione; Antonio Rossi; Carmine Ferrara; Alba Napolitano; Giovanni Palazzolo; Fortunato Ciardiello; Cesare Gridelli |
Related Documents
:
|
23392106 - Prognosis of lung cancer resection in patients with previous extra-respiratory solid ma... 23649446 - Treatment of stage iv non-small cell lung cancer: diagnosis and management of lung canc... 23540866 - Dose-escalation study of three-dimensional conformal thoracic radiotherapy with concurr... 23496196 - Prognostic and predictive factors in resected non-small-cell lung cancer. 9213306 - The limits of surgical resection alone for non-small cell lung cancer. 12013116 - Conversion of laparoscopy to laparotomy due to adnexal malignancy. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2013-1-17 |
Journal Detail:
|
Title: Targeted oncology Volume: - ISSN: 1776-260X ISO Abbreviation: Target Oncol Publication Date: 2013 Jan |
Date Detail:
|
Created Date: 2013-1-17 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101270595 Medline TA: Target Oncol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of Clinical and Experimental Medicine, Second University of Naples, Naples, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Chemoenzymatic total synthesis of hyperiones A and B.
Next Document: Intrastromal femtosecond laser-based presbyopia correction.